Gastrointestinal Stromal Tumors: all 345 studies
Page 4 of 4. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibCompletedNCT00570635Phase 2
- Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT00568750Phase 2
- Phase 1 Study of OSI-930 in Cancer PatientsCompletedNCT00513851Phase 1
- Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
- Gastrointestinal Stromal Tumors (GIST) RegistryCompletedNCT00507273
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GISTCompletedNCT00500188Phase 2
- Ph II Study of Perifosine Plus Gleevec for Patients With GISTCompletedNCT00455559Phase 2
- Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With ImatinibCompletedNCT00441155Phase 1
- Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
- Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs MaintenanceCompletedNCT00367861Phase 3
- Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GISTCompletedNCT00359333Phase 2
- Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal TumorsCompletedNCT00293124Phase 3
- Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)Status unknownNCT00290485Phase 2
- Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)CompletedNCT00276302Phase 1
- Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal TumorsCompletedNCT00254267Phase 2
- Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)CompletedNCT00237172Phase 2
- Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
- Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT00135005Phase 1
- PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to ImatinibCompletedNCT00117299Phase 2
- Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
- Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT00112632Phase 2
- Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorCompletedNCT00103168Phase 3
- Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By SurgeryCompletedNCT00098579Phase 1
- A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248Approved for marketingNCT00094029
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedNCT00091078Phase 2
- Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)CompletedNCT00089960Phase 2
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
- CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal TumorCompletedNCT00087074Phase 2
- Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain TumorCompletedNCT00069940Phase 1
- Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00041249Phase 2
- Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
- Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of ChildhoodCompletedNCT00030667Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During SurgeryCompletedNCT00025246Phase 2
- Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorTerminatedNCT00009906Phase 3
- STI571 in Treating Patients With Recurrent or Refractory Soft Tissue SarcomaCompletedNCT00006357Phase 1/2
- Nitrocamptothecin in Treating Patients With Soft Tissue SarcomasCompletedNCT00005874Phase 2
- SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue SarcomasCompletedNCT00005862Phase 2
- S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal TumorsCompletedNCT00005597Phase 2
- Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal CancerCompletedNCT00005049Phase 2
- Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel ObstructionCompletedNCT00004911Phase 1/2
- Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal ObstructionCompletedNCT00004910Phase 1/2
- Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by SurgeryCompletedNCT00004895Phase 2
- Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00003939Phase 2